Sign up free to see prices on this bond
Free accounts get 40 bond price views per month — 4× the anonymous quota. Pro is unlimited.
About this bond
AI BRIEF · GROUNDED IN STRUCTURED DATABiogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Source: Wikipedia →Risk analytics
SEMI-ANNUAL · BULLET · PAR 100Price history
Sherpa Signal
AS OF 2026-05-07Institutional footprint · signal-level holdings
Sherpa Signal is derived from a panel of tracked institutional portfolios. Names of individual holders are not disclosed.
RFQ routing · coming soon
Security details
VIA OPENFIGIIssuer curve
BIIB · 8 PTSYield (%) plotted against years-to-maturity. This bond highlighted in amber.
Bonds like this
HEURISTICSame currency & sector, maturity within 7 years. Ranked by overlapping institutional owners, issuer match, and rating distance.